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Dear Dr. Beyersdorf,
Herewith we would like to submit our manuscript, entitled 'Programmed electrical
stimulation guided encircling cryoablation concomitant to surgical ventricular
reconstruction for primary prevention of ventricular arrhythmias' for publication in
European Journal of Cardio-Thoracic Surgery.
There are only little data on the occurrence of ventricular arrhythmias (VA) and the
potential benefit from ICDs in patients who have undergone surgical ventricular
restoration (SVR) for ischemic heart failure.
The manuscript systematically evaluated the incidence, type and timing of VA after
programmed electrical stimulation (PES)-guided endocardial cryoablation concomitant
to SVR in patients without previously documented VA during long-term follow-up. The
rational of this approach was to target two potential VA mechanisms - scar related
reentry and VA due to increased wall stress.
We compared the outcome of patients without spontaneous VA, who were referred for
SVR and underwent pre-operative PES prior to surgery and who received concomitant
endocardial cryoablation of the scar borderzone, if inducible for aneurysm-related VA
to a historical cohort of patients without spontaneous VA who did not undergo  pre-
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
operative PES and anti-arrhythmic surgery. We found that the majority of patients
referred for SVR without previously documented VA was inducible for aneurysm
related VA and that during follow-up more than one third of the patients experienced
appropriate ICD therapy. No difference in VA occurrence, VA cycle length and ICD
therapy was observed during long-term follow-up between patients with PES-guided
concomitant cryoablation and those without preoperative evaluation and concomitant
treatment. Improvement in hemodynamics and concomitant EC in inducible patients
appeared not to be sufficient to prevent VAs in this patient population. Considering the
favorable long term survival but high incidence of appropriate ICD therapies, other
concomitant antiarrhythmic surgical approaches targeting the potential arrhythmogenic
substrate need to be considered..
All authors have read and approved submission of the manuscripts and the manuscript
has not been published or is not being considered for publication elsewhere. The
authors have no conflicts of interest to report.
We hope that the manuscript is suitable for publication in European Journal of Cardio-
Thoracic Surgery.
Looking forward to your response at your best convenience, we remain,
Sincerely,
K. Zeppenfeld, MD, PhD
Department of Cardiology
Leiden University Medical Center
Email: K.Zeppenfeld@lumc.nl
Abstract: Background
Surgical ventricular reconstruction (SVR) is an effective treatment to improve left
ventricular (LV) function in patients with ischemic heart failure and a LV anterior-apical
aneurysm. Ventricular arrhythmia (VA) is an important cause for morbidity and mortality
in these patients. Encircling cryoablation (EC) targeting the VA-substrate may therefore
be required. Programmed electrical stimulation (PES) can identify patients at risk for
VA.
Objective
The objective of this study was to evaluate the incidence and type of VA during long-
term follow-up after PES-guided EC concomitant to SVR for primary prevention of VA.
Methods
Thirty-eight patients without spontaneous VA referred for SVR who underwent pre-
operative PES were included (PES-group); 27 patients inducible for aneurysm-related
VA received cryoablation (71%). A historical cohort of 39 patients without spontaneous
VA, pre-operative PES and anti-arrhythmic surgery served as control group. Patients
were discharged with an implantable cardioverter defibrillator (ICD).
Results
During 74±35 months follow-up no arrhythmic deaths occurred. Five-year survival for
the total study population was 78%. Twenty-eight patients (36%) experienced ≥1 VA.
There were no differences in number and type of ICD therapies between groups:
shocks p=0.699; Anti-tachypacing p=0.403. Five-year VA-free survival was 61% for the
PES-group and 65% for the control group (hazard ratio 1.67, p=0.290).
Conclusion
The majority of patients referred for SVR without previously documented VA was
inducible for aneurysm-related VA. During follow-up, more than one third of patients
experienced sustained VA and 25% received appropriate ICD therapy. No difference in
VA occurrence or ICD therapy was observed between groups.
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ABSTRACT 27 
Background 28 
Surgical ventricular reconstruction (SVR) is an effective treatment to improve left ventricular (LV) 29 
function in patients with ischemic heart failure and a LV anterior-apical aneurysm. Ventricular 30 
arrhythmia (VA) is an important cause for morbidity and mortality in these patients. Encircling 31 
cryoablation (EC) targeting the VA-substrate may therefore be required. Programmed electrical 32 
stimulation (PES) can identify patients at risk for VA.  33 
Objective 34 
The objective of this study was to evaluate the incidence and type of VA during long-term follow-up 35 
after PES-guided EC concomitant to SVR for primary prevention of VA. 36 
Methods 37 
Thirty-eight patients without spontaneous VA referred for SVR who underwent pre-operative PES 38 
were included (PES-group); 27 patients inducible for aneurysm-related VA received cryoablation 39 
(71%). A historical cohort of 39 patients without spontaneous VA, pre-operative PES and anti-40 
arrhythmic surgery served as control group. Patients were discharged with an implantable 41 
cardioverter defibrillator (ICD). 42 
Results 43 
During 74±35 months follow-up no arrhythmic deaths occurred. Five-year survival for the total study 44 
population was 78%. Twenty-eight patients (36%) experienced ≥1 VA. There were no differences in 45 
number and type of ICD therapies between groups: shocks p=0.699; Anti-tachypacing p=0.403. Five-46 
year VA-free survival was 61% for the PES-group and 65% for the control group (hazard ratio 1.67, 47 
p=0.290).  48 
Conclusion 49 
The majority of patients referred for SVR without previously documented VA was inducible for 50 
aneurysm-related VA. During follow-up, more than one third of patients experienced sustained VA 51 
and 25% received appropriate ICD therapy. No difference in VA occurrence or ICD therapy was 52 
observed between groups. 53 
 54 
Key words: Ventricular Arrhythmias; Ischemic Heart Failure; Surgical Ventricular Reconstruction; 55 
Cryoablation 56 
57 
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INTRODUCTION 58 
Late sudden cardiac death due to ventricular arrhythmias (VA) constitutes 30-50% of mortality in 59 
patients with ischemic heart failure.1,2 VA may be due to scar-related reentry typically involving the 60 
scar-borderzone or to heart failure related mechano-electric changes resulting in altered ion channel 61 
and transporter function.3-5 Surgical ventricular reconstruction (SVR) is an effective treatment to 62 
reduce left ventricle (LV) volumes and improve LV function in ischemic heart failure patients with LV 63 
anterior-apical aneurysm.6,7 However, despite improved function and reduced wall stress patients 64 
remain at risk for VA.3,8,9 These VA can be due to reentry in the scar-borderzone which is left in place 65 
and excluded by patch material during surgery.10 Targeting aneurysm scar-borderzone without 66 
additional mapping by an encircling cryoablation (EC) has been proven safe and effective for 67 
recurrent slow VA in these patients.11-13 Programmed electrical stimulation (PES) can identify patients 68 
at risk for VA after myocardial infarction as it indicates the presence of an arrhythmogenic 69 
substrate.14,15 Patients who undergo SVR for an LV anterior-apical aneurysm without prior VA who are 70 
inducible for aneurysm-related reentrant VA, may benefit from substrate modification by concomitant 71 
EC of the scar-borderzone referred to as PES-guided EC, to prevent spontaneous VA.  72 
 The objective of this study was to evaluate the incidence, type and timing of VAs after PES-73 
guided EC concomitant to SVR for primary prevention of VA during long-term follow-up. 74 
 75 
METHODS 76 
Patient population 77 
In 2007 PES-guided EC of the scar-borderzone was added to the standard clinical protocol for 78 
patients without documented VA accepted for SVR. The studied population consisted of 38 79 
consecutive patients with ischemic heart failure and anterior-apical aneurysm, who underwent PES 80 
prior to elective SVR and PES-guided EC between 2007 and 2012 (PES-group). Thirty-nine patients 81 
who underwent SVR without PES-guided EC for the same indication from 2003 onwards served as a 82 
historical control group. This included a comprehensive preoperative evaluation with 83 
echocardiography and coronary angiography. The results were evaluated by a team of cardiologists 84 
and cardiothoracic surgeons.  85 
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The Dutch Central Committee on Human-related Research allows use of anonymous data without 86 
prior approval of an institutional review board provided that the data are acquired for patient care. All 87 
data used for this study were acquired for clinical purposes and handled anonymously. 88 
 89 
Preoperative electrophysiological evaluation 90 
Before PES, anti-arrhythmic drugs were discontinued for ≥5 half-lives. None used amiodarone at time 91 
of PES. Two catheters were inserted through the right femoral vein, one placed at the His position 92 
and the second at the right ventricular apex and subsequently in the right ventricular outflow tract to 93 
perform PES. The PES protocol consisted of 3 drive cycle lengths (CL) (600,500,400ms) with 1-3 94 
ventricular extra stimuli (down to 200ms or refractory period) and incremental burstpacing. An 95 
aneurysm-related VA substrate was assumed if PES induced a monomorphic VA, lasting >30s or 96 
requiring termination because of hemodynamic compromise, was re-inducible and the VA exit site 97 
was located at the aneurysm scar-borderzone. The presumed exit site was determined based on the 98 
VA 12-lead electrocardiogram morphology.16 All 12-lead VA electrocardiograms were analyzed by 2 99 
independent observers. In case of discrepancy agreement was reached by consensus. Patients with 100 
aneurysm-related VA were candidates for EC concomitant to SVR. Patients without aneurysm-related 101 
VA underwent SVR only.  102 
 103 
Surgical technique 104 
Patients underwent SVR according to the previously described technique.7 Operations were 105 
performed using cardiopulmonary bypass, aortic cross-clamping and intermittent warm blood 106 
cardioplegia. The LV was opened through the infarcted area. At the transitional zone between viable 107 
and scarred myocardium, EC was performed using a 4mm diameter malleable cryoprobe (Cardioblate 108 
CryoFlex,Medtronic,Minneapolis,USA) using argon gas. Overlapping linear applications, down to -109 
150˚C for 90s, were made to the aneurysm scar-borderzone.10 After EC, a Fontan-stich was placed at 110 
the transitional zone. The residual LV cavity was shaped and sized using a mannequin balloon at 111 
55ml/m2body surface-area (TRISVR,Chase Medical,Richardson,USA) and the remaining defect was 112 
closed through an endoventricular Dacron patch plasty. Excluded fibrous scar-tissue was sutured over 113 
the patch to improve hemostasis. Additional concomitant procedures were performed when indicated. 114 
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After weaning the patient from extracorporeal circulation, trans-esophageal echocardiography was 115 
repeated to assess LV shape and function, patch integrity and valvular competency.   116 
 117 
ICD settings  118 
In patients without ICD before surgery one was implanted before discharge based on the preoperative 119 
LV ejection fraction (EF) ≤30-35% according to current European Society of Cardiology guidelines. 120 
Devices were programmed according to our standard institutional protocol for primary prevention; VA 121 
monitor zone (VACL 321-400ms, no therapy), VA zone (VACL 261-320ms, anti-tachycardia pacing 122 
(ATP) and if the VA continued ICD shocks), VF zone (VACL ≤260ms, ICD shocks). Settings were 123 
adapted when clinically indicated.  124 
 125 
Follow-up 126 
Patients were prospectively followed in an outpatient heart failure program and maintained on optimal 127 
medical treatment for heart failure. ICDs were interrogated every 6 months. Printouts were reviewed 128 
for the occurrence of sustained VA, VACL and therapy mode. VA were classified as sustained when 129 
lasting >30s in the ICD monitor zone or when initiated appropriate ICD therapy. Therapy was 130 
considered appropriate when occurring in response to any VA. Echocardiography was performed 131 
before discharge and afterwards annually.   132 
 133 
Statistical analysis 134 
Continuous variables are expressed as mean(standard deviation) or median(interquartile range [IQR]) 135 
and categorical variables as percentages(%), where appropriate. Student’s T-test, Mann-Whitney U-136 
test, Fishers exact or Chi2-test were used to compare variables between groups at baseline. For 137 
analysis purposes, for each patient the mean CL of all induced and/or spontaneous VAs was 138 
calculated. Intrapatient comparison for LVEF, NYHA-class and VACL was performed using the paired 139 
samples T-test or Wilcoxon paired-test as appropriate. Incidence rate ratio were estimated for counted 140 
data. Univariate and multivariate Cox regression models were constructed to study overall survival 141 
and VA-free survival. Selection of potential confounders was based on clinical knowledge and 142 
comparing baseline characteristics. Furthermore, overall survival and VA-free survival over time were 143 
analysed for the total study population by the method of Kaplan-Meier. All tests were 2-sided and a p-144 
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 6 
value of <0.05 was considered significant. Statistical analyses were performed using SPSS software 145 
(version 22,SPSS Inc,Chicago,Ill,USA). 146 
 147 
RESULTS 148 
Patient characteristics  149 
Thirty-eight patients were included in the PES-group and 39 controls. Baseline patient’s 150 
characteristics are provided in Table 1. Patients were on optimal medical treatment for heart failure 151 
before undergoing SVR. 152 
 153 
Preoperative electrophysiological evaluation 154 
28/38 patients were inducible for 34 monomorphic sustained VAs. Based on the 12-lead 155 
electrocardiogram, 31/34 induced VAs in 27(71%) patients were classified as aneurysm-related. 156 
These had a VACL of 259±54ms, 24 VAs (77%) a superior axis, and 19 VAs (58%) had a left bundle 157 
branch block-type morphology; 17 VAs (55%) were hemodynamically not tolerated. In 2 patients 1 158 
aneurysm-related and 1 non-aneurysm-related VA were induced and in 1 patient only a non-159 
aneurysm-related VA was induced.  160 
 161 
Surgical characteristics 162 
All patients underwent SVR. EC was applied at the aneurysm scar-borderzone in all patients inducible 163 
for aneurysm-related VA. No statistical differences in surgical data were observed between groups 164 
(Table 1).  165 
 166 
Follow-up  167 
Patients were followed for 74±35 months. 74/77 patients had an ICD during follow-up (96%); 3 168 
patients in the PES-group did not receive an ICD at the preference of the referring cardiologist 169 
(LVEF≥35% at discharge, negative PES). There was an improvement in NYHA-class from the 170 
majority in 3 at baseline to 2 at 1 year follow-up (p<0.001). Mean LVEF improved from 27±8% pre-171 
operatively to 36±9% after 1 year (p<0.001). No differences were observed between groups after 1 172 
year (Table 2).  173 
 174 
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VA occurrence and survival 175 
In 28/74 (38%) patients 99 VA episodes were recorded on ICD (VACL 310±58ms, 3[IQR 1-3] 176 
VAs/patient), which prompted appropriate ICD therapy in 26/28 patients (93%); 19 patients (25%) 177 
received ATP for 58 VAs and 11 patients (14%) received ≥1 shocks for 18 VAs. In 10 patients 15 VA 178 
were registered in the VF-zone. No differences were found between groups regarding type of ICD 179 
therapy (Table 2). Two patients in the PES-group had 2 VA registered only in the monitor zone of the 180 
ICD and did not receive any ICD therapy. None of the patients without ICD had documented or 181 
suspected sustained VA.  182 
 Median time to first VA was 11 months (IQR 2-27). 9/ 28 patients (32%) experienced a first 183 
VA while on anti-arrhythmic drugs. Anti-arrhythmic drugs were initiated because of postoperative 184 
spontaneous VA (n=4) or atrial fibrillation/flutter (n=5).  185 
 VA occurrence was similar between groups; 14/38 (37%) patients in the PES-group 186 
experienced 45 VAs (CL 314±50ms; 3[IQR 1-3] VAs/patient), and 14/39 (36%) in the control group 187 
experienced 54 VAs (CL 305±67ms, 3[IQR 1-3] VAs/patient). VA-free survival was 63% at 5 years for 188 
the entire cohort and similar between groups (Figure 1A); 61% for the PES-group and 65% for the 189 
control group (hazard ratio 1.13 [p=0.750]; after adjusting for confounders hazard ratio 1.67 [p=0.290], 190 
Table 3). At multivariate Cox regression analyses for VA occurrence LVEF at baseline demonstrated 191 
to influence VA occurrence: Lower LVEF increased the risk for VA during follow-up.  VA 192 
characteristics did not differ between groups (Table 2). One patient in the control group underwent 193 
successful catheter ablation of 2 presumptive clinical VAs 46 months after discharge and was free 194 
from VA afterwards.  195 
 Twenty-five patients (32%) died during follow-up; 16 patients (64%) died of heart failure. No 196 
arrhythmic deaths were reported. Nine patients died of non-cardiac causes. One patient in the PES-197 
group received a LV assist device as destination therapy 58 months after SVR and 1 patient in the 198 
Control group underwent heart transplantation after 28 months; both were censored for further follow-199 
up afterwards. Kaplan-Meier analysis revealed a 5-year overall survival of 78%. No significant 200 
difference in 5-year overall survival was observed between groups (PES-group 79% versus Control 201 
group 78%, Figure 1B): unadjusted hazard ratio 1.05, p=0.932; adjusted hazard ratio 1.62, p=0.514. 202 
When performing multivariate analyses, only older age remained significantly associated with worse 203 
overall survival (Table 4).  204 
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 205 
Encircling cryoablation and VA characteristics 206 
Overall 11/27 patients (41%) with concomitant EC experienced 37 VA episodes (median 2 [IQR 1-3] 207 
episodes/patient). VACL did not differ between patients with or without EC: 308±46ms versus 311±66, 208 
p=0.919, respectively. Five VA (14%) were terminated by ICD shock and 19 VA (51%) by ATP. The 209 
remaining 13 VA (35%) were registered in the ICD monitor zone. There were no differences in type of 210 
ICD therapy between patients with or without EC.  211 
 212 
DISCUSSION 213 
The present study is the first to systematically evaluate the incidence, type and timing of VA in 214 
patients who underwent PES-guided EC concomitant to SVR for primary prevention of VA thereby 215 
targeting two potential VA mechanisms; scar-related reentry and wall stress. The main findings are: 216 
(1) the majority of patients referred for SVR without previously documented VA was inducible for 217 
aneurysm-related VA; (2) during follow-up more than one third of the patients experienced appropriate 218 
ICD therapy, despite concomitant EC targeting the scar-borderzone and significant hemodynamic 219 
improvement; (3) no difference in VA occurrence, VACL and ICD therapy was observed during long-220 
term follow-up between patients with PES guided concomitant EC and those without preoperative 221 
evaluation and concomitant treatment.  222 
 223 
Pre-operative VA inducibility  224 
The current investigation comprised of a homogeneous patient group, with a large anterior scar after 225 
infarction, the majority in NYHA-class 3 and none treated with amiodarone. 71% of these patients 226 
were inducible for an aneurysm-related VA prior to surgery, using a standardized and complete PES 227 
protocol. Others have reported lower inducibility rates, ranging from 22-58%. However, included 228 
patients were more heterogeneous (with/without apical aneurysm; anterior/non-anterior infarction; 229 
NYHA-class 1-3; many on sotalol/amiodarone; LVEF >40%) and in several studies the induction 230 
protocol was less extensive which is likely to influence inducibility rates in scar-related VA.14,17-20 231 
Induction of a monomorphic reentrant VA indicates the presence of an arrhythmogenic substrate and 232 
has been associated with VA occurrence and sudden death in patients after myocardial infarction, 233 
especially in patients with a LV aneurysm.14,15,21 Based on VA morphology all but 3 VAs had an exit 234 
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site at the aneurysm scar-borderzone in particular involving the inferior apical septal segments. 235 
Therefore, targeting the scar-borderzone by cryoablation may abolish at least parts of the substrate 236 
for these VA. 237 
 238 
VA occurrence after SVR 239 
Previous studies have demonstrated that the substrate for reentrant VA can persist after SVR and 240 
may lead to VA occurrence during follow-up.11,22 This might be partly due to incomplete elimination of 241 
VA substrate by SVR as a significant portion of myocardial scar is left behind the inserted patch for 242 
stability and hemostasis. Excluded portion of the scar containing the VA reentry circuit can no longer 243 
be approached by endocardial catheter ablation, which may further justify preventive substrate 244 
elimination.10 In the historical control group without additional PES guided EC, 36% experienced 245 
spontaneous VA during long-term follow-up supporting the importance of preventive methods to 246 
identify and target possible VA substrates. Of importance, in the PES-group, 71% of which underwent 247 
EC of the scar-borderzone, a similar high VA occurrence rate was registered (37%). Although not 248 
randomized, patient groups were comparable in baseline and surgical characteristics suggesting that 249 
PES-guided concomitant EC does not prevent late VA. This is confirmed by the multivariate Cox 250 
regression analysis demonstrating that PES-guided EC did not influence outcome.  251 
 As VA were registered in 41% of patients who underwent EC of the scar-borderzone the 252 
technique seems insufficient to eliminate the VA substrate in our population. Catheter mapping 253 
studies of post infarct VA have shown that although reentry circuit exit sites are usually located at the 254 
scar-borderzone, which may also involve the mid-wall and subepicardial layers, the critical isthmus is 255 
often found in the electroanatomical dense scar.4,5,23,24  A prior animal study could demonstrate that 256 
endocardial cryoablation lesions reach a depth of approximately 4.8mm.25 Endocardial cryolesions, in 257 
particular at the septal scar-borderzone may not create transmural or deep lesions and may not be 258 
sufficient to eliminate or exclude the VA substrate, allowing for circuits to remain or the reentrant 259 
circuit to exit.  260 
 VA occurrence rate after EC in this population without prior VA was higher than previously 261 
described recurrence rates in patients who underwent EC for the treatment of recurrent VA.3,9,11-13 262 
This may be in part explained by the large proportion of patients with an ICD (96%) in the current 263 
investigation allowing for reliable monitoring of VA recurrence. The high ICD implantation rate is 264 
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different from most prior studies with implantation rates of only up to 9.6% after SVR,3,11-13 except for 265 
the investigation of O’Neill9 in which 48% of patients were discharged with an ICD. Differences in 266 
surgical techniques and the frequent use of amiodarone in the prior studies may have also contributed 267 
to lower VA recurrence rates.  268 
 Of importance, differences in VA substrate may exist between patients with, as in previous 269 
studies, and without, as in the current study, spontaneous VA before surgery. While previous studies 270 
mainly included patients with hemodynamically tolerated and often slow VA,10,12,26 the observed VAs 271 
in the present study were often fast, and an important number required ICD shocks to be terminated. 272 
As the underlying substrate determines VA characteristics, like CL, the occurrence of fast VAs may 273 
reflect differences in the VA substrate between the studied population and patients in previous 274 
studies.27 Fast VTs as observed in our cohort, may be due to small anatomical or even functional 275 
reentry circuits. The substrate for these fast VAs may not be sufficiently targeted by EC of the scar-276 
borderzone.   277 
 The fact that late VA in both groups were similar regarding CL and response to ATP, supports 278 
the conclusion that EC had no sufficient impact on the VA substrate. Progressive remodeling and LV 279 
re-enlargement may occur after surgery contributing to arrhythmogenity, which  is also supported by 280 
the high occurrence rate of atrial fibrillation in patients with VA.10,20 281 
 282 
Survival 283 
We reported a good overall survival of 78% at 5 years follow-up for the total study population. This is 284 
comparable with other centers with a large experience in SVR (70-82% 5 years survival).3,11,28 285 
Furthermore, no arrhythmic deaths occurred. However, the observed fast VAs terminated by ICD 286 
shock in 11 patients (14%), may be considered as aborted arrhythmic deaths. Of interest, two prior 287 
studies reported similar rates of arrhythmic deaths (17% and 20%).8,13 In contrast, in 1 study cardiac 288 
death constituted 19% of late mortality at follow-up, however sudden cardiac death rate was only 289 
2.5%.3 Although not all ICD therapy equals aborted sudden death, most of the study period was 290 
during the time with relatively short detection times and prior to MADIT-RIT trial results were 291 
published, symptomatic and potential fatal VT do occur.29  292 
 293 
Clinical implications 294 
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The majority of patients referred for SVR and without prior VA were inducible for aneurysm-related 295 
monomorphic VA prior to SVR. Although all pre-operatively inducible patients underwent concomitant 296 
EC targeting the scar-borderzone this was not sufficient to prevent VA in a considerable number of 297 
patients. Improvement in hemodynamics and concomitant EC in inducible patients appeared not to be 298 
sufficient to prevent VAs in this patient population. Considering the good long-term survival and high 299 
incidence of appropriate ICD therapies, other concomitant antiarrhythmic surgical approaches 300 
targeting the potential arrhythmogenic substrate like endocardectomy should be (re-)considered; 301 
techniques, which have been successfully performed with favorable results in the early days of 302 
arrhythmia surgery.30    303 
 304 
Limitations 305 
Because of the retrospective nature of the study the number of patients included is limited. As a 306 
consequence of the inclusion of a historical control group, follow-up duration varied among patients. 307 
Furthermore, this study was non-randomized. No comparison between patients with inducible 308 
aneurysm-related VA but without concomitant EC was performed. However, because of the reported 309 
favorable results of non-mapping guided cryoablation to treat VA, not performing cryoablation in these 310 
high-risk patients was considered unethical. Although the treatment strategy was not allocated in a 311 
randomized fashion, groups were comparable and treated by the same team. The cohort was too 312 
small to evaluate a predictive value of a negative preoperative PES.  313 
 314 
Conclusion 315 
The majority of patients referred for SVR without previously documented VA was inducible for 316 
aneurysm-related fast monomorphic VA. Despite concomitant EC targeting the scar-borderzone, 317 
postoperative hemodynamic improvement and low all-cause mortality, 5 year VA-free survival was 318 
only 64%. No difference in VA occurrence or ICD therapy was observed between patients with or 319 
without PES-guided concomitant EC. Other strategies for targeting the substrate for VA in this patient 320 
population are required.  321 
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TABLES 330 
Table 1.Baseline characteristics 331 
 All 
N=77 
PES-group 
N=38 
Control 
group 
N=39 
P-value 
Male, n(%) 60(78) 28(74) 32(82) 0.376 
Age,years 60±10 63±9 58±11 0.051 
Diabetes mellitus,n(%) 16(21) 10(26) 6(15) 0.237 
Atrial fibrillation,n(%) 8(10) 6(16) 2(5) 0.125 
MI-SVR duration,months(IQR) 36(9-144) 48(10-180) 28(7-132) 0.133 
NTproBNP,pg/mL(IQR) 1358  
(572-2151) 
1346  
(616-2253) 
1369 
(459-1885) 
0.518 
Primary reperfusion,n(%) 25(32) 8(21) 17(44) 0.035 
NYHA,n(%)    <0.001 
Class 2 19(25) 17(45) 2((5)  
Class 3 53(68) 21(55) 32(82)  
Class 4 5(6) 0 5(13)  
Euroscore,n(IQR) 6(4-14) 6 (4-14) 7(4-18) 0.537 
LVEF,% 27±8 29±8 25±7 0.015 
LVESV-index,ml/m2 80±45 81±52 79±39 0.880 
LVEDV-index,ml/m2 111±53 110±63 112±44 0.894 
ACE-I/ARB,n(%) 74(96) 37(98) 37(95) 0.571 
Beta-blocker,n(%) 74(96) 37(98) 37(95) 0.571 
MRA,n(%) 46(60) 26(68) 20(51) 0.125 
     
CABG,n(%) 41(53) 21(55) 20(51) 0.915 
MVR,n(%) 45(58) 21(55) 24(62) 0.576 
TVR,n(%) 26(34) 11(29) 15(38) 0.377 
AVR,n(%) 4(5) 2(5) 2(5) 0.979 
Patch-size,cm2 14±8 12±5 16±10 0.070 
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CPB-time,min 204±58 209±52 194±68 0.349 
ACC-time,min 141±58 148±41 129±43 0.124 
ACC=Aortic cross-clamp; ACEi=angiotensin-converting enzyme inhibitor; ARB=angiotensin 
receptor blocker; CPB=Corporal-pulmonary bypass; AVR=Aortic valve replacement; 
CABG=Coronary angiography bypass graft; EDV=End-diastolic volume; EF=Ejection 
fraction; ESV=End-systolic volume; LV=Left ventricle; MI=myocardial infarction; MVR=Mitral 
valve repair; MRA=Mineralocorticoid receptor antagonists; NYHA=New York Heart 
Association; SVR=surgical ventricular reconstruction; TVR=Tricuspid valve repair 
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Table 2.Follow-up  334 
 All 
N=77 
PES-group 
N=38 
Control 
group 
N=39 
P-value* 
Follow-up,months 74±35 61±25 87±39 <0.001 
Death(all cause),n(%) 25(32) 12(32) 13(33) 0.869 
Cardiac death,n(%) 14(18) 9(24) 7(18) 0.688 
ICD,n(%) 74(96) 35(92) 39(100) 0.115 
CRT,n(%) 44(57) 23(61) 21(54) 0.299 
Anti-arrhythmic drug,n(%) 36(47) 17(42) 19(49) 0.726 
Sotalol≥160mg/day 26(34) 13(34) 13(33) 0.953 
Amiodarone 21(27) 10(26) 11(28) 0.852 
New atrial fibrillation,n(%) 33(43) 15(39) 18(46) 0.544 
NYHA 1 year follow-up,n(%)    0.052 
Class 1 28(39) 19(54) 9(26)  
Class 2 33(47) 14(39) 19(53)  
Class 3 10(14) 3(8) 7(20)  
LVEF,% 36±9 36±8 35±9 0.845 
LVESV-Index,ml/m2 50±19 50±19 51±19 0.829 
LVEDV-Index,ml/m2 77±22 76±23 79±23 0.600 
     
VA     
Total,n 99 45 54 0.982 
Incidence rate, episodes/total 
follow-up 
0.017 0.016 0.019 1.19 
(0.78-1.80)† 
VA occurrence,patients(%) 28(36) 14(37) 14(36) 0.931 
Time to first VA,months(IQR) 11(2-27) 8(2-26) 15(4-29) 0.511 
VA episodes/patients(IQR) 3(1-3) 3(1-3) 3(1-3) 0.982 
VA cycle length,ms 310±58 314±50 305±67 0.699 
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Ventricular fibrillation,n  15 8 7 0.841 
ICD therapy,patients(%) 26(34) 12(32) 14(36) 0.222 
ATP,patients(%) 
Episodes,n 
19(25) 
58 
8(24) 
19 
11(28) 
39 
0.403 
 
Shock,patients(%) 
Episodes,n 
11(14) 
18 
6(16) 
9 
5(13) 
9 
0.699 
 
Monitor zone,patients(%) 
Episodes,n 
8(10) 
22 
6(16) 
16 
2(5) 
6 
0.092 
 
AAD usage during first VA episode 9(12) 5(13) 4(10) 1.0 
Sotalol≥160mg/day 6 4 2  
Amiodarone 3 1 2  
Abbreviations as in Table 1. CRT=cardiac resynchronization therapy. VA=ventricular arrhythmia 
* p-value calculated between groups 
† Incidence rate ratio (95% confidence interval) 
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Table 3.Cox Regression analyses:VA-free survival 337 
 
Univariate Multivariate 
HR(CI 95%) P-value HR(CI 95%) P-value 
Age 1.02(0.98-1.07) 0.28 1.03(0.99-1.08) 0.13 
LVEF baseline 0.97(0.92-1.02) 0.19 0.94(0.89-1.00) 0.03 
NYHA-class* 1.15(0.53-2.50) 0.72 1.28(0.51-3.18) 0.60 
PES-group 1.13(0.53-2.41) 0.75 1.67(0.65-4.30) 0.29 
Primary reperfusion 0.81(0.35-1.84) 0.61 0.83(0.35-1.99) 0.68 
Sex 1.81(0.62-5.23) 0.28 2.62(0.87-7.89) 0.09 
CI=Confidence interval; HR=Hazard ratio; Abbreviations as Table 1 
* NYHA-class as categorical covariate did not alter outcome 
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Table 4.Cox Regression analyses:Overall survival 340 
 
Univariate Multivariate 
P-value HR(CI 95%) P-value HR(CI 95%) 
Age 0.02 1.10(1.02-1.18) <0.01 1.12(1.03-1.22) 
LVEF baseline 0.59 0.98(0.91-1.05) 0.16 0.94(0.87-1.024) 
NYHA-class* 0.24 1.98(0.64-6.10) 0.15 2.54(0.72-8.91) 
PES-group 0.93 1.05(0.35-3.12) 0.51 1.62(0.38-6.85) 
Primary reperfusion 0.24 0.41(0.09-1.84) 0.33 0.45(0.09-2.25) 
Sex 0.35 2.05(0.45-9.25) 0.28 2.45(0.48-12.49) 
CI=Confidence interval; HR=Hazard ratio; Abbreviations as in Table 1 
* NYHA-class as categorical covariate did not alter the outcome 
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FIGURE LEGENDS 343 
Figure 1.Survival analyses 344 
A: Kaplan Meier curves of 5 year ventricular arrhythmia (VA)-free survival, groups compared using 345 
multivariate Cox regression model. B: Kaplan Meier curves of 5 year overall survival, groups 346 
compared using multivariate Cox regression model. Curves are according to the different pre-347 
operative strategies of yes/no programmed electrical stimulation (PES). 348 
349 
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FIGURES 350 
Figure 1 351 
352 
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